The Efficacy of Mirabegron in the Treatment of Urgency and the Potential Utility of Combination Therapy

Overview

Journal Ther Adv Urol

Publisher Sage Publications

Date 2018 Jul 24

PMID 30034543

Citations 2

Authors

Karl-Erik Andersson

Nurul Choudhury

Jean-Nicolas Cornu

Moses Huang

Cees Korstanje

Emad Siddiqui

Philip Van Kerrebroeck

Affiliations

Soon will be listed here.

Abstract

Urgency is the prevalent and most bothersome symptom of overactive bladder (OAB) and the treatment of urgency is the primary objective in the management of OAB. Urgency has a major impact on other symptoms of OAB and culminates in an increased frequency of micturition and reduced volume voided, which may contribute to shorter intervals between the need to void. Antimuscarinic agents and mirabegron, a β-adrenoceptor agonist, constitute the main oral pharmacotherapeutic options for the treatment of urgency and other OAB symptoms. The reduction of urgency and other OAB symptoms significantly improve health-related quality of life. This review will explore the distinct mechanisms of action and effects of antimuscarinic agents and mirabegron, in relation to their effect on the pathophysiology of urgency. The review will also provide an overview of the various validated measurements of urgency and the numerous clinical trials regarding antimuscarinic agent monotherapy, mirabegron monotherapy, or combination treatment with mirabegron added on to the antimuscarinic agent solifenacin. A narrative review of the literature relating to pathophysiology of urgency, the validated measurements of urgency, and clinical trials relating to the pharmacological treatment of urgency. Antimuscarinic agent monotherapy, mirabegron monotherapy, or combination treatment with mirabegron added on to the antimuscarinic agent solifenacin statistically significantly reduce the symptoms of urgency compared with placebo. Combination therapy with mirabegron added on to solifenacin also statistically significantly reduces the symptoms of severe urgency compared with antimuscarinic agent monotherapy. A critique of the clinical benefits of combination therapy is also provided. Combination therapy provides an alternative treatment in patients with OAB that includes urgency who respond poorly to first-line monotherapy and who may otherwise often move on to more invasive treatments.

Citing Articles

Mirabegron Alleviates the Degree of Burden Experienced by Caregivers of Older Females with Mixed or Urge Incontinence: A Prospective Study.

Zachariou A, Filiponi M, Kaltsas A, Dimitriadis F, Champilomatis I, Paliouras A Clin Interv Aging. 2021; 16:291-299.

PMID: 33628016 PMC: 7897712. DOI: 10.2147/CIA.S283737.

Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists.

Okui N World J Urol. 2019; 37(11):2459-2466.

PMID: 30687908 PMC: 6825634. DOI: 10.1007/s00345-019-02644-7.

References

Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H . Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol. 2005; 174(5):2032-6. DOI: 10.1097/01.ju.0000176793.50410.9e. View

Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R . Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2014; 67(3):577-88. DOI: 10.1016/j.eururo.2014.02.012. View

Homma Y, Yamaguchi O . A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2009; 16(5):499-506. DOI: 10.1111/j.1442-2042.2009.02286.x. View

Staskin D, Rosenberg M, Sand P, Zinner N, Dmochowski R . Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009; 63(12):1715-23. DOI: 10.1111/j.1742-1241.2009.02189.x. View

Karram M, Toglia M, Serels S, Andoh M, Fakhoury A, Forero-Schwanhaeuser S . Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology. 2008; 73(1):14-8. DOI: 10.1016/j.urology.2008.08.485. View

Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M . In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats. Naunyn Schmiedebergs Arch Pharmacol. 2012; 386(3):247-53. DOI: 10.1007/s00210-012-0821-4. View

Kato D, Uno S, Van Schyndle J, Fan A, Kimura T . Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis. Int J Urol. 2017; 24(10):757-764. DOI: 10.1111/iju.13422. View

Siegel S, Noblett K, Mangel J, Griebling T, Sutherland S, Bird E . Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2014; 34(3):224-30. DOI: 10.1002/nau.22544. View

Nixon A, Colman S, Sabounjian L, Sandage B, Schwiderski U, Staskin D . A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol. 2005; 174(2):604-7. DOI: 10.1097/01.ju.0000165461.38088.7b. View

10.

Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun C, Weinstein D . The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008; 54(3):543-62. DOI: 10.1016/j.eururo.2008.06.047. View

11.

Ikeda Y, Kanai A . Urotheliogenic modulation of intrinsic activity in spinal cord-transected rat bladders: role of mucosal muscarinic receptors. Am J Physiol Renal Physiol. 2008; 295(2):F454-61. PMC: 2519189. DOI: 10.1152/ajprenal.90315.2008. View

12.

Cartwright R, Srikrishna S, Cardozo L, Robinson D . Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder. BJU Int. 2010; 107(10):1612-7. DOI: 10.1111/j.1464-410X.2010.09684.x. View

13.

Nitti V, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S . Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2012; 189(4):1388-95. DOI: 10.1016/j.juro.2012.10.017. View

14.

Rouget C, Rekik M, Camparo P, Botto H, Rischmann P, Lluel P . Modulation of nerve-evoked contractions by β3-adrenoceptor agonism in human and rat isolated urinary bladder. Pharmacol Res. 2014; 80:14-20. DOI: 10.1016/j.phrs.2013.12.006. View

15.

Cardozo L, Hessdorfer E, Milani R, Arano P, Dewilde L, Slack M . Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int. 2008; 102(9):1120-7. DOI: 10.1111/j.1464-410X.2008.07939.x. View

16.

Kanai A, Wyndaele J, Andersson K, Fry C, Ikeda Y, Zabbarova I . Researching bladder afferents-determining the effects of β(3) -adrenergic receptor agonists and botulinum toxin type-A. Neurourol Urodyn. 2011; 30(5):684-91. DOI: 10.1002/nau.21102. View

17.

Michel M, Chapple C . Basic mechanisms of urgency: roles and benefits of pharmacotherapy. World J Urol. 2009; 27(6):705-9. PMC: 2780647. DOI: 10.1007/s00345-009-0446-5. View

18.

Iijima K, De Wachter S, Wyndaele J . Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol. 2007; 52(3):842-7. DOI: 10.1016/j.eururo.2007.02.057. View

19.

Yamaguchi O, Uchida E, Higo N, Minami H, Kobayashi S, Sato H . Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial. Int J Urol. 2013; 21(6):586-93. DOI: 10.1111/iju.12372. View

20.

Abrams P . Urgency: the key to defining the overactive bladder. BJU Int. 2005; 96 Suppl 1:1-3. DOI: 10.1111/j.1464-410X.2005.05648.x. View